Within the newest dustup over a groundbreaking HIV prevention medication, Medical doctors With out Borders has harshly criticized the producer for refusing to promote its therapy on to humanitarian organizations.
The transfer got here after months of talks during which Medical doctors With out Borders requested Gilead Sciences for a “restricted” provide of lenacapavir. The drug has been in demand after research confirmed a single set of injections each six months can provide nearly full safety from an infection, a type of prevention often known as preexposure prophylaxis, or PrEP.
STAT Plus: The decades-long journey to Gilead’s twice-a-year HIV prevention drug lenacapavir
The group at the moment obtains lenacapavir by way of The International Fund to Battle AIDS, Tuberculosis and Malaria, a worldwide partnership of governments, civil society teams, and the personal sector that, in late 2024, reached a cope with the corporate to distribute lenacapavir to 2 million individuals in low- and middle-income international locations.

This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans

